Mona Ashiya - 29 May 2026 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Reporting relationship: Director
Issuer ticker: STTK
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 20:00:06 UTC
Prior SEC filing: 02 Sep 2025
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew R. Neill, Attorney-in-Fact for Dr. Mona Ashiya

Key filing fact

Mona Ashiya filed Form 4 for Shattuck Labs, Inc. (STTK) on 02 Jun 2026.

Key facts

This page summarizes Mona Ashiya's Form 4 filing for Shattuck Labs, Inc. (STTK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 02 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794070 Primary reporting owner

Ashiya Mona

Relationship: Director
Address: C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN
Signature: /s/ Andrew R. Neill, Attorney-in-Fact for Dr. Mona Ashiya
Signature date: 02 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STTK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +81,000
Change %
Price: $0.000000^*
Shares after: 81,000
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 81,000
Exercise price: $5.95
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.